Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant Melanoma

NCT00911443 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

488

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Melanoma

Interventions

BIOLOGICAL: Dacarbazine + Interferon alpha + Thymosin-alpha-1 1.6 mg
BIOLOGICAL: Dacarbazine + Interferon alpha + Thymosin-alpha-1 3.2 mg
BIOLOGICAL: Dacarbazine + Interferon alpha + Thymosin-alpha-1 6.4 mg
BIOLOGICAL: Dacarbazine + Thymosin-alpha-1 3.2 mg
DRUG: Dacarbazine + Interferon alpha

Sponsor

sigma-tau i.f.r. S.p.A.